Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 115 articles:
HTML format
Text format



Single Articles


    January 2018
  1. YANG X, Pan Y, Qiu Z, Du Z, et al
    RNF126 as a biomarker of a poor prognosis in invasive breast cancer and CHK1 inhibitor efficacy in breast cancer cells.
    Clin Cancer Res. 2018 Jan 11. pii: 1078-0432.CCR-17-2242.
    PubMed     Text format     Abstract available


  2. MAGBANUA MJM, Rugo HS, Wolfe DM, Hauranieh L, et al
    Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assess biomarker status and biology over time.
    Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2312.
    PubMed     Text format     Abstract available


  3. DAVILA-GONZALEZ D, Choi DS, Rosato RR, Granados-Principal S, et al
    Pharmacological inhibition of NOS activates ASK1/JNK pathway augmenting docetaxel-mediated apoptosis in triple negative breast cancer.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1437.
    PubMed     Text format     Abstract available


    December 2017
  4. MASTORAKI S, Strati A, Tzanikou E, Chimonidou M, et al
    ESR1 methylation: a liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment.
    Clin Cancer Res. 2017 Dec 28. pii: 1078-0432.CCR-17-1181.
    PubMed     Text format     Abstract available


  5. ZHAO EY, Shen Y, Pleasance E, Kasaian K, et al
    Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.
    Clin Cancer Res. 2017;23:7521-7530.
    PubMed     Text format     Abstract available


    November 2017
  6. LENZ G, Hamilton A, Geng S, Hong T, et al
    t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0824.
    PubMed     Text format     Abstract available


  7. ROSSI G, Mu Z, Rademaker A, Austin L, et al
    Cell-Free DNA and Circulating Tumor Cells: Comprehensive liquid biopsy analysis in Advanced Breast Cancer.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2092.
    PubMed     Text format     Abstract available


  8. AUSHEV VN, Lee E, Zhu J, Gopalakrishnan K, et al
    Novel predictors of breast cancer survival derived from miRNA activity analysis.
    Clin Cancer Res. 2017 Nov 14. pii: clincanres.0996.2017.
    PubMed     Text format     Abstract available


  9. EVANS KW, Yuca E, Akcakanat A, Scott SM, et al
    A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Clin Cancer Res. 2017;23:6468-6477.
    PubMed     Text format     Abstract available


    October 2017
  10. HSU PY, Wu VS, Kanaya N, Petrossian K, et al
    Dual mTOR Kinases MLN0128 Inhibitor Sensitizes HR+/HER2+ Breast Cancer Patient-derived Xenografts to Trastuzumab or Fulvestrant.
    Clin Cancer Res. 2017 Oct 27. pii: clincanres.1983.2017.
    PubMed     Text format     Abstract available


  11. PRICEMAN SJ, Tilakawardane D, Jeang B, Murad JP, et al
    Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2041.2017.
    PubMed     Text format     Abstract available


  12. YU Z, He S, Wang D, Patel HK, et al
    Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.0670.2017.
    PubMed     Text format     Abstract available


    September 2017
  13. LUNDBERG A, Lindstrom LS, Harrell JC, Falato C, et al
    Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.1535.2017.
    PubMed     Text format     Abstract available


  14. TOBIN NP, Lundberg A, Lindstrom LS, Harrell JC, et al
    PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients.
    Clin Cancer Res. 2017 Sep 29. pii: clincanres.2301.2017.
    PubMed     Text format     Abstract available


  15. DOOSTAN I, Karakas C, Kohansal M, Low KH, et al
    Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.
    Clin Cancer Res. 2017 Sep 25. pii: clincanres.1544.2017.
    PubMed     Text format     Abstract available


  16. ZHANG Y, Schroeder BE, Jerevall PL, Ly A, et al
    A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.1688.2017.
    PubMed     Text format     Abstract available


  17. DIOT G, Metz S, Noske A, Liapis E, et al
    Multi-Spectral Optoacoustic Tomography (MSOT) of human breast cancer.
    Clin Cancer Res. 2017 Sep 12. pii: clincanres.3200.2016.
    PubMed     Text format     Abstract available


  18. MA CX, Suman V, Goetz MP, Northfelt DW, et al
    A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer.
    Clin Cancer Res. 2017 Sep 5. pii: clincanres.1260.2017.
    PubMed     Text format     Abstract available


    August 2017
  19. SABBAGHI M, Gil-Gomez G, Guardia C, Servitja S, et al
    Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.
    Clin Cancer Res. 2017 Aug 18. pii: clincanres.0696.2017.
    PubMed     Text format     Abstract available


  20. EMENS LA
    Breast Cancer Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2017 Aug 11. pii: clincanres.3001.2017.
    PubMed     Text format     Abstract available


  21. VAN DER VELDEN BHM, Elias SG, Bismeijer T, Loo CE, et al
    Complementary value of contralateral parenchymal enhancement on DCE-MRI to prognostic models and molecular assays in high-risk ER+HER2- breast cancer.
    Clin Cancer Res. 2017 Aug 8. pii: clincanres.0176.2017.
    PubMed     Text format     Abstract available


    July 2017
  22. FORMISANO L, Stauffer KM, Young CD, Bhola NE, et al
    Association of FGFR1 with ERalphamaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1232.2017.
    PubMed     Text format     Abstract available


  23. SUN J, Meng H, Yao L, Lv M, et al
    Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients.
    Clin Cancer Res. 2017 Jul 19. pii: clincanres.3227.2016.
    PubMed     Text format     Abstract available


  24. UEDA S, Saeki T, Osaki A, Yamane T, et al
    Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: Multimodal functional imaging and multiplex cytokine analysis.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0874.2017.
    PubMed     Text format     Abstract available


  25. RIETHDORF S, Muller V, Loibl S, Nekljudova V, et al
    Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant "Geparquattro" trial.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0255.2017.
    PubMed     Text format     Abstract available


  26. MA CX, Bose R, Gao F, Freedman RA, et al
    Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.0900.2017.
    PubMed     Text format     Abstract available


    June 2017
  27. KENNY T, Schmidt H, Adelson K, Hoshida Y, et al
    Patient-derived interstitial fluids and predisposition to aggressive sporadic breast cancer through collagen remodeling and inactivation of p53.
    Clin Cancer Res. 2017 Jun 19. pii: clincanres.0342.2017.
    PubMed     Text format     Abstract available


  28. TURNER NC, Asghar U, Barr AR, Cutts R, et al
    Single-cell dynamics determines response to CDK4/6 inhibition in triple negative breast cancer.
    Clin Cancer Res. 2017 Jun 12. pii: clincanres.0369.2017.
    PubMed     Text format     Abstract available


  29. REEDER-HAYES KE, Anderson BO
    Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.
    Clin Cancer Res. 2017;23:2655-2664.
    PubMed     Text format     Abstract available


  30. FREEDMAN RA, Partridge AH
    Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer.
    Clin Cancer Res. 2017;23:2647-2654.
    PubMed     Text format     Abstract available


  31. VONDERHEIDE RH, Domchek SM, Clark AS
    Immunotherapy for Breast Cancer: What Are We Missing?
    Clin Cancer Res. 2017;23:2640-2646.
    PubMed     Text format     Abstract available


  32. YATES LR, Desmedt C
    Translational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer.
    Clin Cancer Res. 2017;23:2630-2639.
    PubMed     Text format     Abstract available


  33. NIK-ZAINAL S, Morganella S
    Mutational Signatures in Breast Cancer: The Problem at the DNA Level.
    Clin Cancer Res. 2017;23:2617-2629.
    PubMed     Text format     Abstract available


  34. PARTRIDGE AH, Carey LA
    Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?
    Clin Cancer Res. 2017;23:2611-2616.
    PubMed     Text format     Abstract available


    May 2017
  35. SCHOTT AF, Goldstein L, Cristofanilli M, Ruffini PA, et al
    Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC).
    Clin Cancer Res. 2017 May 24. pii: clincanres.2748.2016.
    PubMed     Text format     Abstract available


  36. REINHOLZ MM, Chen B, Dueck AC, Tenner K, et al
    IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831.
    Clin Cancer Res. 2017 May 22. doi: 10.1158/1078-0432.CCR-15-0574.
    PubMed     Text format     Abstract available


  37. DICKLER MN, Tolaney S, Rugo HS, Cortes J, et al
    MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.
    Clin Cancer Res. 2017 May 22. pii: clincanres.0754.2017.
    PubMed     Text format     Abstract available


  38. SHAASHUA L, Shabat-Simon M, Haldar R, Matzner P, et al
    Perioperative COX-2 and β-adrenergic blockade improves metastatic biomarkers in breast cancer patients in a phase-II randomized trial.
    Clin Cancer Res. 2017 May 10. pii: clincanres.0152.2017.
    PubMed     Text format     Abstract available


  39. SILWAL-PANDIT L, Nord S, von der Lippe Gythfeldt H, Moller EK, et al
    The longitudinal transcriptional response to neoadjuvant chemotherapy with and without bevacizumab in breast cancer.
    Clin Cancer Res. 2017 May 9. pii: clincanres.0160.2017.
    PubMed     Text format     Abstract available


  40. XU X, De Angelis C, Burke KA, Nardone A, et al
    HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.
    Clin Cancer Res. 2017 May 9. pii: clincanres.2191.2016.
    PubMed     Text format     Abstract available


  41. BIHANI T, Patel HK, Arlt H, Tao N, et al
    Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has anti-tumor activity in multiple ER+ breast cancer patient-derived xenograft models.
    Clin Cancer Res. 2017 May 4. pii: clincanres.2561.2016.
    PubMed     Text format     Abstract available


  42. TORRES-ADORNO AM, Lee J, Kogawa T, Ordentlich P, et al
    Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer.
    Clin Cancer Res. 2017 May 2. pii: clincanres.2622.2016.
    PubMed     Text format     Abstract available


    April 2017
  43. PIEROBON M, Ramos C, Wong S, Hodge KA, et al
    Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.2656.2016.
    PubMed     Text format     Abstract available


  44. WEERTS MJA, Hollestelle A, Sieuwerts AM, Foekens JA, et al
    Low Tumor Mitochondrial DNA Content is Associated with Better Outcome in Breast Cancer Patients Receiving Anthracycline-based Chemotherapy.
    Clin Cancer Res. 2017 Apr 18. pii: clincanres.0032.2017.
    PubMed     Text format     Abstract available


  45. ASSADIPOUR Y, Zacharakis N, Crystal JS, Prickett TD, et al
    Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2017 Apr 4. pii: clincanres.1423.2016.
    PubMed     Text format     Abstract available


    March 2017
  46. SOMLO G, Frankel P, Arun B, Ma CX, et al
    Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 29. pii: clincanres.2714.2016.
    PubMed     Text format     Abstract available


  47. PITRODA S, Bao R, Andrade J, Weichselbaum RR, et al
    Low Recombination Proficiency Score (RPS) predicts heightened sensitivity to DNA-damaging chemotherapy in breast cancer.
    Clin Cancer Res. 2017 Mar 24. pii: clincanres.2845.2016.
    PubMed     Text format     Abstract available


  48. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    PubMed     Text format     Abstract available


  49. SCHWARTZBERG LS, Yardley D, Elias A, Patel M, et al
    A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2339.2016.
    PubMed     Text format     Abstract available


  50. JOVANOVIC B, Mayer IA, Mayer EL, Abramson VG, et al
    A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC).
    Clin Cancer Res. 2017 Mar 7. pii: clincanres.3055.2016.
    PubMed     Text format     Abstract available


  51. MA CX, Gao F, Luo J, Northfelt DW, et al
    NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer.
    Clin Cancer Res. 2017 Mar 7. pii: clincanres.3206.2016.
    PubMed     Text format     Abstract available


    February 2017
  52. HUSING A, Fortner RT, Kuhn T, Overvad K, et al
    Added value of serum hormone measurements in risk prediction models for breast cancer for women not using exogenous hormones: Results from the EPIC cohort.
    Clin Cancer Res. 2017 Feb 28. pii: clincanres.3011.2016.
    PubMed     Text format     Abstract available


    January 2017
  53. SHACHAR SS, Deal AM, Weinberg M, Williams GR, et al
    Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane Based Chemotherapy for Early Stage Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2266.2016.
    PubMed     Text format     Abstract available


  54. SINGER CF, Tan YY, Fitzal F, Steger GG, et al
    Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
    Clin Cancer Res. 2017 Jan 31. pii: clincanres.2373.2016.
    PubMed     Text format     Abstract available


  55. DEGNIM AC, Hoskin TL, Arshad M, Frost MH, et al
    Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.
    Clin Cancer Res. 2017 Jan 26. pii: clincanres.2026.2016.
    PubMed     Text format     Abstract available



  56. Retraction: Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90.
    Clin Cancer Res. 2017;23:612.
    PubMed     Text format    


  57. AFGHAHI A, Timms KM, Vinayak S, Jensen KC, et al
    Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
    Clin Cancer Res. 2017 Jan 13. pii: clincanres.2174.2016.
    PubMed     Text format     Abstract available


  58. HART CD, Vignoli A, Tenori L, Uy GL, et al
    Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
    Clin Cancer Res. 2017 Jan 12. doi: 10.1158/1078-0432.CCR-16-1153.
    PubMed     Text format     Abstract available


  59. WU J, Cui Y, Sun X, Cao G, et al
    Unsupervised clustering of quantitative image phenotypes reveals breast cancer subtypes with distinct prognoses and molecular pathways.
    Clin Cancer Res. 2017 Jan 10. pii: clincanres.2415.2016.
    PubMed     Text format     Abstract available


  60. CARDILLO TM, Sharkey RM, Rossi DL, Arrojo R, et al
    Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP-inhibitors in BRCA1/2-wild-type triple-negative breast cancer.
    Clin Cancer Res. 2017 Jan 9. pii: clincanres.2401.2016.
    PubMed     Text format     Abstract available


  61. MOULDER-THOMPSON S, Borges VF, Baetz TD, Mcspadden T, et al
    Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC).
    Clin Cancer Res. 2017 Jan 4. pii: clincanres.1496.2016.
    PubMed     Text format     Abstract available


    December 2016
  62. LIU Y, Burness ML, Martin-Trevino R, Guy J, et al
    RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2016 Dec 29. doi: 10.1158/1078-0432.CCR-15-1348.
    PubMed     Text format     Abstract available


  63. HUMPHRIES MP, Sundara Rajan S, Droop A, Suleman C, et al
    A Case Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic and Tractable Biomarkers in Male Breast Cancer.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.1952.2016.
    PubMed     Text format     Abstract available


  64. CONNOLLY R, Li H, Jankowitz RC, Zhang Z, et al
    Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.1729.2016.
    PubMed     Text format     Abstract available


  65. JANKOWITZ RC, Oesterreich S, Lee AV, Davidson NE, et al
    New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and other Targeted Therapies.
    Clin Cancer Res. 2016 Dec 15. pii: clincanres.0591.2016.
    PubMed     Text format     Abstract available


  66. LECONET W, Chentouf M, Du Manoir S, Chevalier C, et al
    Therapeutic activity of anti-AXL antibody against triple-negative breast cancer Patient Derived Xenografts and metastasis.
    Clin Cancer Res. 2016 Dec 6. pii: clincanres.1316.2016.
    PubMed     Text format     Abstract available


    November 2016
  67. HOSFORD SR, Dillon LM, Bouley SJ, Rosati R, et al
    Combined inhibition of both p110alpha and p110beta isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER+ breast cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.2764.2015.
    PubMed     Text format     Abstract available


  68. PRAT A, Lluch A, Turnbull AK, Dunbier AK, et al
    A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.2092.2016.
    PubMed     Text format     Abstract available


  69. HUNT KK, Karakas C, Ha MJ, Biernacka A, et al
    Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
    Clin Cancer Res. 2016 Nov 23. pii: clincanres.2217.2016.
    PubMed     Text format     Abstract available


  70. LAMBERTS LE, Koch M, de Jong JS, Adams A, et al
    Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study.
    Clin Cancer Res. 2016 Nov 9. pii: clincanres.0437.2016.
    PubMed     Text format     Abstract available


  71. BOZOVIC-SPASOJEVIC I, Zardavas D, Brohee S, Ameye L, et al
    The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.
    Clin Cancer Res. 2016 Nov 9. pii: clincanres.0979.2016.
    PubMed     Text format     Abstract available


  72. ELEBRO K, Borgquist S, Rosendahl AH, Markkula A, et al
    High estrogen receptor beta expression is prognostic among adjuvant chemotherapy-treated patients - results from a population-based breast cancer cohort.
    Clin Cancer Res. 2016 Nov 3. pii: clincanres.1095.2016.
    PubMed     Text format     Abstract available


  73. BRAND JS, Hedayati E, Humphreys K, Ludvigsson JF, et al
    Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients.
    Clin Cancer Res. 2016;22:5249-5255.
    PubMed     Text format     Abstract available


    October 2016
  74. CHAN N, Willis A, Kornhauser N, Ward MM, et al
    Influencing the tumor microenvironment: Phase 2 Study of Copper depletion with tetrathiomolybdate in high risk breast cancer and preclinical models of lung metastases.
    Clin Cancer Res. 2016 Oct 21. pii: clincanres.1326.2016.
    PubMed     Text format     Abstract available


  75. ZEMBUTSU H, Nakamura S, Akashi ST, Kuwayama T, et al
    Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer; a Prospective Multicenter Study.
    Clin Cancer Res. 2016 Oct 19. pii: clincanres.1779.2016.
    PubMed     Text format     Abstract available


  76. BRECHBUHL HM, Finlay-Schultz J, Yamamoto T, Gillen A, et al
    Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen.
    Clin Cancer Res. 2016 Oct 4. pii: clincanres.2851.2015.
    PubMed     Text format     Abstract available


  77. MERCOGLIANO MF, De Martino M, Venturutti L, Rivas MA, et al
    TNFalpha-induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.0970.2016.
    PubMed     Text format     Abstract available


  78. ZUO WJ, Jiang YZ, Wang YJ, Xu XE, et al
    Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.
    Clin Cancer Res. 2016;22:4859-4869.
    PubMed     Text format     Abstract available


    September 2016
  79. RENNERT G, Pinchev M, Gronich N, Saliba W, et al
    Oral bisphosphonates and improved survival of breast cancer.
    Clin Cancer Res. 2016 Sep 28. pii: clincanres.0547.2016.
    PubMed     Text format     Abstract available



  80. Correction: Novel Antitumor Effect of Estradiol in Athymic Mice Injected with a T47D Breast Cancer Cell Line Overexpressing Protein Kinase C Alpha.
    Clin Cancer Res. 2016;22:4756.
    PubMed     Text format    


  81. LIPS EH, Debipersad R, Scheerman CE, Mulder L, et al
    BRCA1-mutated estrogen receptor positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0198.2016.
    PubMed     Text format     Abstract available


  82. NIELSEN TO, Jensen MB, Burugu S, Gao D, et al
    High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.1278.2016.
    PubMed     Text format     Abstract available


  83. VON WAHLDE MK, Timms KM, Chagpar AB, Wali VB, et al
    Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer.
    Clin Cancer Res. 2016 Sep 6. pii: clincanres.0889.2016.
    PubMed     Text format     Abstract available



  84. Correction: Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
    Clin Cancer Res. 2016;22:4536.
    PubMed     Text format    


  85. QUINTELA-FANDINO M, Lluch A, Manso LM, Calvo I, et al
    18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: a window-of-opportunity randomized trial.
    Clin Cancer Res. 2016 Sep 1. pii: clincanres.0738.2016.
    PubMed     Text format     Abstract available


    August 2016
  86. MCARTHUR HL, Diab A, Page DB, Yuan J, et al
    A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling.
    Clin Cancer Res. 2016 Aug 26. pii: clincanres.0190.2016.
    PubMed     Text format     Abstract available


  87. BRUFSKY AM, Davidson NE
    Multi-parametric genomic assays for breast cancer: Time for the next generation?
    Clin Cancer Res. 2016 Aug 12. pii: clincanres.1513.2016.
    PubMed     Text format     Abstract available


  88. PARSONS HA, Beaver JA, Cimino-Mathews A, Ali SM, et al
    Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple Negative Breast Cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.1543.2016.
    PubMed     Text format     Abstract available


  89. STRULOV SHACHAR S, Deal AM, Weinberg M, Nyrop KA, et al
    Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane Based Chemotherapy.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.0940.2016.
    PubMed     Text format     Abstract available


    July 2016
  90. SAMAEEKIA R, Adorno-Cruz V, Bockhorn J, Chang YF, et al
    MicroRNA-206 inhibits stemness and metastasis of breast cancer by targeting MKL1/IL11 pathway.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0943.2016.
    PubMed     Text format     Abstract available


  91. AL-AZHRI J, Zhang Y, Bshara W, Zirpoli GR, et al
    Tumor Expression of Vitamin D Receptor and Breast Cancer Histopathological Characteristics and Prognosis.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0075.2016.
    PubMed     Text format     Abstract available


  92. WALKER AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, et al
    FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0493.2016.
    PubMed     Text format     Abstract available


    June 2016
  93. KURLAND BF, Peterson LM, Lee JH, Schubert EK, et al
    Estrogen receptor binding (FES PET) and glycolytic activity (FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer.
    Clin Cancer Res. 2016 Jun 24. pii: clincanres.0362.2016.
    PubMed     Text format     Abstract available


  94. SHAW JA, Guttery DS, Hills A, Fernandez-Garcia D, et al
    Mutation analysis of cell-free DNA and single circulating tumor cells in metastatic breast cancer patients with high CTC counts.
    Clin Cancer Res. 2016 Jun 22. pii: clincanres.0825.2016.
    PubMed     Text format     Abstract available


  95. STOVER DG, Coloff JL, Barry WT, Brugge JS, et al
    The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis.
    Clin Cancer Res. 2016 Jun 21. pii: clincanres.0471.2016.
    PubMed     Text format     Abstract available


  96. PATEL H, Abduljabbar R, Lai CF, Periyasamy M, et al
    CDK7, cyclin H and MAT1 is elevated in breast cancer and is prognostic in estrogen receptor- positive breast cancer.
    Clin Cancer Res. 2016 Jun 14. pii: clincanres.1104.2015.
    PubMed     Text format     Abstract available


  97. SHARMA P, Lopez-Tarruella S, Garcia-Saenz JA, Ward C, et al
    Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts.
    Clin Cancer Res. 2016 Jun 14. pii: clincanres.0162.2016.
    PubMed     Text format     Abstract available


  98. LI W, O'Shaughnessy JA, Hayes DF, Campone M, et al
    Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.2452.2015.
    PubMed     Text format     Abstract available


  99. WANG ZQ, Milne K, Derocher H, Webb JR, et al
    CD103 and Intratumoral Immune Response in Breast Cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.0732.2016.
    PubMed     Text format     Abstract available


  100. ALVES CL, Elias D, Lyng MB, Bak M, et al
    High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.1984.2015.
    PubMed     Text format     Abstract available


  101. SESTAK I, Zhang Y, Schroeder BE, Schnabel CA, et al
    Cross Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in women with hormone receptor positive lymph-node negative early stage breast cancer.
    Clin Cancer Res. 2016 Jun 1. pii: clincanres.0155.2016.
    PubMed     Text format     Abstract available



  102. Correction: Hydroxychloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer.
    Clin Cancer Res. 2016;22:2825.
    PubMed     Text format    


    May 2016
  103. LYLE LT, Lockman PR, Adkins CE, Mohammad AS, et al
    Alterations in Pericyte Subpopulations are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer.
    Clin Cancer Res. 2016 May 31. pii: clincanres.1836.2015.
    PubMed     Text format     Abstract available


  104. SPEERS C, Zhao SG, Kothari V, Santola A, et al
    Maternal embryonic leucine zipper kinase (MELK) as a novel mediator and biomarker of radioresistance in human breast cancer.
    Clin Cancer Res. 2016 May 25. pii: clincanres.2711.2015.
    PubMed     Text format     Abstract available


  105. INGOLD HEPPNER B, Untch M, Denkert C, Pfitzner BM, et al
    Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2-positive breast cancer.
    Clin Cancer Res. 2016 May 17. pii: clincanres.2338.2015.
    PubMed     Text format     Abstract available


  106. JESELSOHN R, Barry WT, Migliaccio I, Biagioni C, et al
    TransCONFIRM: Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer.
    Clin Cancer Res. 2016 May 16. pii: clincanres.0148.2016.
    PubMed     Text format     Abstract available


  107. GYANCHANDANI R, Lin Y, Lin HM, Cooper KL, et al
    Intra-tumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer.
    Clin Cancer Res. 2016 May 16. pii: clincanres.2889.2015.
    PubMed     Text format     Abstract available


  108. KLINTMAN M, Buus R, Cheang MC, Sheri A, et al
    Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease.
    Clin Cancer Res. 2016;22:2405-16.
    PubMed     Text format     Abstract available


  109. DENNISON JB, Shahmoradgoli M, Liu W, Ju Z, et al
    High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype.
    Clin Cancer Res. 2016 May 12. pii: clincanres.0171.2016.
    PubMed     Text format     Abstract available


  110. MITRI Z, Nanda R, Blackwell K, Costelloe CM, et al
    TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
    Clin Cancer Res. 2016 May 10. pii: clincanres.2845.2015.
    PubMed     Text format     Abstract available


  111. GILANI R, Phadke S, Bao LW, Lachacz E, et al
    UM-164: a potent c-Src/p38 kinase inhibitor with in vivo activity against triple negative breast cancer.
    Clin Cancer Res. 2016 May 6. pii: clincanres.2158.2015.
    PubMed     Text format     Abstract available


    February 2016
  112. PODO F, Santoro F, Di Leo G, Manoukian S, et al
    Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    Clin Cancer Res. 2016;22:895-904.
    PubMed     Text format     Abstract available


  113. SAMENI M, Tovar EA, Essenburg CJ, Chalasani A, et al
    Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Clin Cancer Res. 2016;22:923-34.
    PubMed     Text format     Abstract available


  114. CHU D, Paoletti C, Gersch C, VanDenBerg DA, et al
    ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients.
    Clin Cancer Res. 2016;22:993-9.
    PubMed     Text format     Abstract available


  115. ABDEL-FATAH TM, McArdle SE, Agarwal D, Moseley PM, et al
    HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Clin Cancer Res. 2016;22:905-14.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: